Integration of Novel Agents into the Care of Patients with Multiple Myeloma

• Type of Material: Article
• Authors: Robert Z. Orlowski, The University of Texas MD Anderson Cancer Center; Sagar Lonial, Emory University
• Language: English
• Date: 2016-11-15
• Publisher: American Association for Cancer Research
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2016 American Association for Cancer Research.
• Final Published Version (URL): http://dx.doi.org/10.1158/1078-0432.CCR-16-0861
• Title of Journal or Parent Work: Clinical Cancer Research
• ISSN: 1078-0432
• Volume: 22
• Issue: 22
• Start Page: 5443
• End Page: 5452
• Grant/Funding Information: R.Z. Orlowski, the Florence Maude Thomas Cancer Research Professor, was supported by The MD Anderson Cancer Center SPORE in Multiple Myeloma (P50 CA142509), The MD Anderson Cancer Center Support Grant (P30 CA016672), the NCI (U10 CA032102, R01 CA184464 and CA194264), the Brock Family Myeloma Research Fund, and the MD Anderson Cancer Center High Risk Multiple Myeloma Moon Shot.; S. Lonial would like to acknowledge support from the Levine Family Foundation and the Richard and Annelly Deets Fund for Multiple Myeloma.
• Keywords: Life Sciences & Biomedicine; REFRACTORY MYELOMA; DARATUMUMAB MONOTHERAPY; RANDOMIZED PHASE-2; INTERNATIONAL STAGING SYSTEM; Science & Technology; ORAL PROTEASOME INHIBITOR; HUMANIZED MONOCLONAL-ANTIBODY; Oncology; OPEN-LABEL; STEM-CELL TRANSPLANTATION; WORKING GROUP; LOW-DOSE DEXAMETHASONE
• Research Categories: Health Sciences, Oncology

Abstract

The pace of therapeutic drug development in multiple myeloma has reached unprecedented levels, with five regulatory approvals for relapsed and/or refractory disease of either new drugs or new drug regimens in 2015, one already in 2016, and still others anticipated. This has provided a wide array of options to be considered by patients and their health care providers in the event of relapse after or progression on front-line therapy. Most of these agents are currently being evaluated in earlier patient populations, including as parts of induction, consolidation, and maintenance therapy approaches, where their benefits may be even greater. Moreover, additional randomized studies have been completed with our previous stable of novel agents that inform their use in these settings as well. In the current contribution to this CCR Focus on multiple myeloma, we will present an overview of some of the key recent data that have supported the addition of these new therapeutics to our armamentarium against multiple myeloma. Also, we will provide some guidelines about possible best practices in applying these regimens and attempt to extrapolate how they will be used as parts of our future standards of care.